Form 4: Steve Elms Reports Acquisition of ADMA Biologics Stock and Options

Director Steve Elms reports acquisition of ADMA Biologics stock and options, including restricted stock units and stock options, while disclaiming beneficial ownership of shares held by Aisling Capital II LP except to the extent of his pecuniary interest.

Summary

• Steve Elms, a director of ADMA Biologics, reported acquiring 24,040 shares of common stock through restricted stock units (RSUs) on February 26, 2024.
• These RSUs will vest in two equal installments over a year.
• Elms also acquired 37,541 stock options with an exercise price of $5.40, vesting monthly over one year, and expiring on March 26, 2034.
• He directly owns 76,441 shares of common stock.
• Elms is associated with Aisling Capital II LP, which owns 3,615,671 shares, but he disclaims beneficial ownership except for his pecuniary interest.
• The report was filed on February 28, 2024.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisitions could be seen as positive, but it's not a major event.

Positives

• Acquisition of shares and options by a director may signal confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment.

Key Dates